Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2017;154(2):360–373.28823862
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412. doi:10.1016/S0140-6736(12)60643-623374478
   PubMed Web of Science ®Google Scholar
• Liu Y, Xiong Z, Beasley A, D’Amico T, Chen XL. Personalized and targeted therapy of esophageal squamous cell carcinoma: an update. Ann N Y Acad Sci. 2016;1381(1):66–73. doi:10.1111/nyas.1314427399176
   PubMedGoogle Scholar
• Park MS, Dong SM, Kim BR, et al. Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts. Oncotarget. 2014;5(13):4929–4934. doi:10.18632/oncotarget.206324952635
   PubMedGoogle Scholar
• André T, Chastre E, Kotelevets L. et al. Tumoral angiogenesis: physiopathology, prognostic value and therapeutic perspectives. Rev Med Interne. 1998;904–913. doi:10.1016/S0248-8663(99)80063-09887458
   PubMed Web of Science ®Google Scholar
• Li CH, Xue JS, Shi SN, et al. Overexpression of IQGAP1 promotes the angiogenesis of esophageal squamous cell carcinoma through the AKT and ERK?mediated VEGF?VEGFR2 signaling pathway. Oncol Rep. 2018;40(3):1795–1802. doi:10.3892/or.2018.655830015941
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.10201732335505
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Aisner DL, Wood DE, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–821. doi:10.6004/jnccn.2018.006230006423
   PubMed Web of Science ®Google Scholar
• Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634–1657. doi:10.1093/annonc/mdy19230032243
   PubMed Web of Science ®Google Scholar
• Nie K, Geng C, Zhang L, et al. Clinical observation of bevacizumab combined with S-1 in the treatment of pretreated advanced esophageal carcinoma. Chin Med Sci J. 2016;31(4):221–227. doi:10.1016/s1001-9294(17)30004-428065218
   PubMedGoogle Scholar
• Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep. 1995;12(3):271–276. doi:10.1039/np99512002717792073
   PubMed Web of Science ®Google Scholar
• Mathema VB, Koh YS, Thakuri BC, Sillanpaa M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation. 2012;35(2):560–565. doi:10.1007/s10753-011-9346-021603970
   PubMed Web of Science ®Google Scholar
• Ghantous A, Sinjab A, Herceg Z, Darwiche N. Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 2013;18(17–18):894–905. doi:10.1016/j.drudis.2013.05.00523688583
   PubMed Web of Science ®Google Scholar
• D’Anneo A, Carlisi D, Lauricella M, et al. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. 2013;4(10):e891. doi:10.1038/cddis.2013.41524176849
   PubMedGoogle Scholar
• Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother. 2018;107:1488–1495. doi:10.1016/j.biopha.2018.08.13930257366
   PubMed Web of Science ®Google Scholar
• Liu W, Wang X, Sun J, Yang Y, Li W, Song J. Parthenolide suppresses pancreatic cell growth by autophagy-mediated apoptosis. Onco Targets Ther. 2017;10:453–461. doi:10.2147/OTT.S11725028176967
   PubMed Web of Science ®Google Scholar
• Zhu SM, Park YR, Seo SY, Kim IH, Lee ST, Kim SW. Parthenolide inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in colorectal cancer cells. Intest Res. 2019;17(4):527–536. doi:10.5217/ir.2019.0003131426622
   PubMed Web of Science ®Google Scholar
• Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother. 2018;107:1488–1495.30257366
   PubMed Web of Science ®Google Scholar
• Kim SL, Lee S-T, Trang K, et al. Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer. Int J Mol Med. 2014;33(5):1261–1267. doi:10.3892/ijmm.2014.166924573421
   PubMed Web of Science ®Google Scholar
• Li L, Li D. Apoptosis of human esophageal cancer cell EC9706 induced by parthenolide. China J Mod Med. 2010;20:2658–2661.
   Google Scholar
• Liao K, Xia B, Zhuang Q-Y, et al. Parthenolide inhibits cancer stem-like side population of nasopharyngeal carcinoma cells via suppression of the NF-κB/COX-2 pathway. Theranostics. 2015;5(3):302–321. doi:10.7150/thno.838725553117
   PubMed Web of Science ®Google Scholar
• Nakabayashi H, Shimizu K. Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo. BMC Cancer. 2012;12(1):453. doi:10.1186/1471-2407-12-45323039130
   PubMedGoogle Scholar
• Herbein G, Varin A, Fulop T. NF-kappaB, AP-1, zinc-deficiency and aging. Biogerontology. 2006;7(5–6):409–419. doi:10.1007/s10522-006-9056-416964525
   PubMed Web of Science ®Google Scholar
• Fujioka S, Niu J, Schmidt C, Sclabas GM, Chiao PJ. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol. 2004;7806–7819. doi:10.1128/MCB.24.17.7806-7819.200415314185
   PubMed Web of Science ®Google Scholar
• Fortenberry JD, Owens ML, Chen NX, Brown LA. S-nitrosoglutathione inhibits TNF-alpha-induced NFkappaB activation in neutrophils. Inflamm Res. 2001;50(2):89–95. doi:10.1007/s00011005072911289659
   PubMed Web of Science ®Google Scholar
• Justyna Z, Konrad Z, Katarzyna G-U. Expression of chosen cell cycle and proliferation markers in pancreatic intraepithelial neoplasia. Gastroenterol Rev. 2018;13(2):118–126. doi:10.5114/pg.2018.75824
   Google Scholar
• Razavi SM, Yahyaabadi R. Comparative study of correlation between angiogenesis markers (CD31) and Ki67 marker with behavior of aggressive and nonaggressive central giant cell granuloma with immunohistochemistry technique. Asian Pac J Cancer Prev. 2018;19(8):2279–2283. doi:10.22034/APJCP.2018.19.8.227930139237
   PubMedGoogle Scholar
• Wang D, Stockard CR, Harkins L, et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem. 2008;83(3–4):179–189. doi:10.1080/1052029080245108518846440
   PubMed Web of Science ®Google Scholar
• Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163–4169. doi:10.1182/blood-2004-10-413515687234
   PubMed Web of Science ®Google Scholar
• Fang LJ, Shao XT, Wang S, Lu GH, Xu T, Zhou JY. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis. Planta Med. 2010;76(3):258–264. doi:10.1055/s-0029-118608319774508
   PubMed Web of Science ®Google Scholar
• Sohma I, Fujiwara Y, Sugita Y, et al. Parthenolide, an NF-κB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics. 2011;8(1):39–47.21289336
   PubMed Web of Science ®Google Scholar
• Bielenberg DR, Zetter BR. The contribution of angiogenesis to the process of metastasis. Cancer J. 2015;21(4):267–273. doi:10.1097/PPO.000000000000013826222078
   PubMed Web of Science ®Google Scholar
• Gupta MK. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol. 2003;9(6):1144–1155. doi:10.3748/wjg.v9.i6.114412800214
   PubMed Web of Science ®Google Scholar
• van de Schootbrugge C, Bussink J, Span PN, et al. αB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. BMC Cancer. 2013;13:128.23506259
   PubMed Web of Science ®Google Scholar
• Li R, Qi Y, Jiang M, et al. Primary tumor-secreted VEGF induces vascular hyperpermeability in premetastatic lung via the occludin phosphorylation/ubiquitination pathway. Mol Carcinog. 2019;58(12):2316–2326. doi:10.1002/mc.2312031553086
   PubMed Web of Science ®Google Scholar
• Su CH, Wu YJ, Chang CY, et al. The increase of VEGF secretion from endothelial progenitor cells post ultrasonic VEGF gene delivery enhances the proliferation and migration of endothelial cells. Ultrasound Med Biol. 2013;39(1):134–145. doi:10.1016/j.ultrasmedbio.2012.08.01823141902
   PubMed Web of Science ®Google Scholar
• Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–467.30173249
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–4380. doi:10.1200/JCO.2002.10.08812409337
   PubMed Web of Science ®Google Scholar
• Oka D, Nishimura K, Shiba M, et al. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB. Int J Cancer. 2007;120(12):2576–2581. doi:10.1002/ijc.2257017290398
   PubMed Web of Science ®Google Scholar
• Liu JY, Zeng QH, Cao PG, et al. RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-kappaB pathway. Br J Cancer. 2018;118(12):1617–1627. doi:10.1038/s41416-018-0116-829867225
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang D, Ji TF, Shi L, Yu JL. Overexpression of lncRNA ANRIL up-regulates VEGF expression and promotes angiogenesis of diabetes mellitus combined with cerebral infarction by activating NF-κB signaling pathway in a rat model. Oncotarget. 2017;8(10):17347–17359. doi:10.18632/oncotarget.1446828060742
   PubMedGoogle Scholar
• Tino AB, Chitcholtan K, Sykes PH, Garrill A. Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. J Ovarian Res. 2016;9(1):84. doi:10.1186/s13048-016-0293-027906095
   PubMedGoogle Scholar
• Kong FC, Zhang JQ, Zeng C, et al. Inhibitory effects of parthenolide on the activity of NF-kappaB in multiple myeloma via targeting TRAF6. J Huazhong Univ Sci Technolog Med Sci. 2015;35(3):343–349. doi:10.1007/s11596-015-1435-026072071
   PubMedGoogle Scholar
• Li C, Guo S, Shi T. Role of NF-kappaB activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells. Cell Biochem Funct. 2013;31(3):263–268. doi:10.1002/cbf.289923086737
   PubMed Web of Science ®Google Scholar
• Kong F, Chen Z, Li Q, et al. Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism. J Huazhong Univ Sci Technolog Med Sci. 2008;28(5):525–530. doi:10.1007/s11596-008-0508-818846331
   PubMedGoogle Scholar
• Li CJ, Guo SF, Shi TM. Culture supernatants of breast cancer cell line MDA-MB-231 treated with parthenolide inhibit the proliferation, migration, and lumen formation capacity of human umbilical vein endothelial cells. Chin Med J. 2012;125(12):2195–2199.22884152
   PubMed Web of Science ®Google Scholar
• Schmidt D, Textor B, Pein OT, et al. Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J. 2007;26(3):710–719. doi:10.1038/sj.emboj.760153917255940
   PubMed Web of Science ®Google Scholar
• Tischer E. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–11954.1711045
   PubMed Web of Science ®Google Scholar
• Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene. 2003;22(36):5619–5629. doi:10.1038/sj.onc.120664412944910
   PubMed Web of Science ®Google Scholar
• Wu MY, Zhuang CX, Yang HX, Liang YR. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: an immunohistochemical and in situ hybridization study. World J Gastroenterol. 2004;10(4):476–480. doi:10.3748/wjg.v10.i4.47614966901
   PubMed Web of Science ®Google Scholar
• Trop-Steinberg S, Azar Y. AP-1 expression and its clinical relevance in immune disorders and cancer. Am J Med Sci. 2017;353(5):474–483. doi:10.1016/j.amjms.2017.01.01928502334
   PubMed Web of Science ®Google Scholar
• Yoo SM, Lee CJ, An HJ, et al. RSK2-mediated ELK3 activation enhances cell transformation and breast cancer cell growth by regulation of c-fos promoter activity. Int J Mol Sci. 2019;20(8). doi:10.3390/ijms20081994
   Web of Science ®Google Scholar
• Wang Q, Liu H, Wang Q, et al. Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9. PLoS One. 2017;12(6):e0180558. doi:10.1371/journal.pone.018055828665975
   PubMed Web of Science ®Google Scholar
• Kappelmann M, Bosserhoff A, Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. Eur J Cell Biol. 2014;93(1–2):76–81. doi:10.1016/j.ejcb.2013.10.00324315690
   PubMed Web of Science ®Google Scholar
• Wang D, Wang J, Ding N, et al. MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation. Biochem Biophys Res Commun. 2016;473(4):959–965. doi:10.1016/j.bbrc.2016.03.16127045082
   PubMed Web of Science ®Google Scholar
• Gao GY, Ma J, Lu P, Jiang X, Chang C. Ophiopogonin B induces the autophagy and apoptosis of colon cancer cells by activating JNK/c-Jun signaling pathway. Biomed Pharmacother. 2018;108:1208–1215. doi:10.1016/j.biopha.2018.06.17230372822
   PubMed Web of Science ®Google Scholar
• Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409–416. doi:10.1007/s10555-006-9005-316951987
   PubMed Web of Science ®Google Scholar
• Wang Y, Xu J, Zhang X, et al. TNF-alpha-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis. Cell Death Dis. 2017;8(3):e2715. doi:10.1038/cddis.2017.12928358372
   PubMedGoogle Scholar
• Remels AH, Gosker HR, Verhees KJ, Langen RC, Schols AM. TNF-alpha-induced NF-kappaB activation stimulates skeletal muscle glycolytic metabolism through activation of HIF-1alpha. Endocrinology. 2015;156(5):1770–1781. doi:10.1210/en.2014-159125710281
   PubMed Web of Science ®Google Scholar
• Kim M, Jung K, Kim IS, et al. TNF-alpha induces human neural progenitor cell survival after oxygen-glucose deprivation by activating the NF-kappaB pathway. Exp Mol Med. 2018;50(4):14. doi:10.1038/s12276-018-0033-129622770
   PubMedGoogle Scholar